Company profile
SynaptixBio | Leukodystrophies
SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies which affect the brain. SynaptixBio will tackle a specific acute subset of leukodystrophies by altering the expression of a mutated gene identified as causing the disease.
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jul 2024 to 30 Jun 2027
SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies which affect the central nervous system (CNS) in both adults (milder) and children (the most common and severe). TUBB4A-related leukodystrophies are a group of newly described neurodegenerative diseases which are genetic, debilitating, and...
1 Nov 2023 to 30 Apr 2025
SynaptixBio Ltd is a UK-based rare disease biotech SME pioneering ground-breaking development of therapeutics for treatment of TUBB4A-related leukodystrophies - the diseases affect the central nervous system (CNS) in both adults (milder) and children (the most common and severe). Rare diseases affect less than 1:2,000 people and are often severely disabli...
